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Abstract 
Background: Recent data support the renewed interest in hypertriglyceridemia as a possible important therapeutic 
target for cardiovascular risk reduction. This study was designed to address the question of all-cause mortality during 
extended follow-up of the BIP trial in patients stratified by baseline triglyceride levels.
Methods: In the BIP trial 3090 patients with proven coronary artery disease were randomized to bezafibrate 400 mg/
day or placebo. All-cause mortality data after 20 years of follow-up, were obtained from the National Israeli Population 
Registry. Patients with hypertriglyceridemia (triglycerides ≥200 mg/dL, n = 458) were equally distributed among the 
study groups (15 % in both placebo and bezafibrate groups).
Results: During follow-up 1869 patients died (952 in placebo vs. 917 in bezafibrate group). Following multivariate 
adjustment allocation to bezafibrate was associated with small but significant 10 % mortality risk reduction (HR 0.90; 
95 % CI 0.82–0.98, p = 0.026). Variables associated with significantly increased mortality risk were history of a past MI, 
NYHA class, diabetes, age, higher BMI and glucose level. In patients with hypertriglyceridemia multivariate analysis 
demonstrated a 25 % all-cause mortality risk reduction associated with allocation to bezafibrate (HR 0.75, CI 95 % 
0.60–0.94; p = 0.012). In patients without hypertriglyceridemia bezafibrate had no significant effect on long-term 
mortality.
Conclusions: During long-term follow-up bezafibrate-allocated patients experienced a modest but significant 10 % 
reduction in the adjusted risk of mortality. This effect of bezafibrate was more prominent among patients with base-
line hypertriglyceridemia (25 % mortality risk reduction).
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Background
There is a growing body of recently published genetic 
and epidemiological evidences which demonstrated a 
causal role of triglycerides (TG) and TG-rich lipoproteins 
in the pathogenesis of atherosclerosis and particularly 
coronary artery disease (CAD) [1–5]. These data support 
the renewed interest in hypertriglyceridemia as a possi-
ble important therapeutic target for cardiovascular risk 
reduction [6–8]. Historically, one of the main aims of the 
Bezafibrate Infarction Prevention (BIP) trial was to assess 
the effect of reducing TG levels (alongside with rising of 
HDL-C levels) on cardiac risk in patients with established 
CAD [9]. During the course of the study, TG levels were 
reduced by 21  % and HDL-C increased by 18  % among 
patients that had received bezafibrate. Nevertheless, 
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despite these favorable lipid-modifying effects, bezafi-
brate therapy was associated with only a non-significant 
trend of a reduction of the incidence of primary end 
point (fatal or non-fatal myocardial infarction or sud-
den death). However, a significant 39.5  % reduction in 
the primary end point in patients with high baseline TG 
(≥ 200 mg/dl) was observed. Also during post hoc analy-
sis of the BIP trial we have shown that bezafibrate signifi-
cantly reduced the incidence of myocardial infarction in 
patients with the metabolic syndrome [10]. The relatively 
short mean follow-up of 6.2 year which could be achieved 
during the double-blind phase of the BIP trial precluded 
a determination of whether bezafibrate affected total 
mortality. We hypothesized that early favorable effects of 
bezafibrate on lipids and myocardial infarction during the 
original trial period could be translated in a subsequent 
reduction in total mortality during a longer-term obser-
vation. Therefore, this study was designed to address the 
question of mortality during extended 20-year follow-up 
of the BIP trial.
Methods
The BIP trial
The BIP trial evaluated the effect of bezafibrate versus 
placebo on major coronary events and mortality in CHD 
patients. Details of the study design have been previ-
ously published [9, 11–13]. Briefly, 3090 male and female 
patients 45–74  years of age with a history of MI and/or 
stable angina pectoris and a lipid profile of serum total 
cholesterol between 180 and 250 mg/dL, low-density lipo-
protein cholesterol (LDL-C) ≤180  mg/dL (≤160  mg/dL 
for patients <50 years), HDL-C ≤45 mg/dl, and triglycer-
ides ≤300 mg/dL were randomized to bezafibrate 400 mg/
day or placebo between May 1990 and January 1993 and 
followed up over a mean period of 6.2  years (median 
6.2 years; interquartile range [IQR] 5.3–6.8 years).
Stable angina pectoris confirmed by coronary angiog-
raphy, and/or radio- nuclear studies or standard exercise 
tests. The main exclusion criteria were insulin-dependent 
diabetes mellitus, severe heart failure, unstable angina 
pectoris, hepatic or renal failure, known sensitivity to 
bezafibrate, or current use of lipid-modifying drugs.
After discontinuation of the study medication, patients 
were observed for coronary events for an additional 
period, bringing the total follow-up time to a mean of 
8.2  years (median 7.9  years; interquartile range 7.2–
8.7  years). This study reports all-cause mortality data 
obtained in 2014 from the National Israeli Population 
Registry presenting 20  years follow-up [IQR 12–22.6]. 
The identification number recorded during enrollment 
was matched to mortality data stored at the national reg-
ister and verified by matching date of birth. The current 
analysis is based on over 52,100 patient-years data.
Study population
In the present analysis we included all the subjects 
included in the original BIP randomized study with 
the exception of 19 subjects that did not take any study 
medication. Excluded patients were equally distributed 
between the Bezafibrate and placebo arm (9 and 10 
patients, respectively). IRB approval was obtained both 
for the original study and for the current long term fol-
low-up data acquisition.
Statistical analysis
Variables were expressed as mean ± SD, and categorical 
data were summarized as percentages. Baseline charac-
teristics of patients with patients with TG ≥200  mg/dL 
by the original treatment allocation group were com-
pared using the Chi-square test for categorical parame-
ters and Student t test or Mann–Whitney for continuous 
variables, as appropriate. Similarly, we compared the 
pre-specified subgroups of subjects with baseline tri-
glycerides levels ≥200 mg/dL to those with lower levels 
of triglycerides. The supplemental online data includes 
characteristics and comparison of the entire study popu-
lation by original allocation to bezafibrate or placebo.
Survival curves were constructed by the Kaplan–Meier 
method, and the significance of the variation between them 
was assessed using a Log-rank test. We compared survival 
for the entire study population by original treatment alloca-
tion (placebo vs. bezafibrate), followed by survival analysis 
by treatment allocation in the pre-specified sub-groups of 
subject with TG ≥200 mg/dL and <200 mg/dL.
We used multivariate Cox proportional hazards regres-
sion modeling in order to explore the adjusted risk reduc-
tion associated with bezafibrate treatment in the entire 
study population and separately in the subgroup of 
patients with TG ≥200 mg/dL. Covariates were selected 
if univariate association was significant (p < 0.05) or clini-
cal studies have demonstrated robust association with 
prognosis in previous studies. The following covariates 
were selected using the best subset method: age, gen-
der, BMI, prior MI, history of diabetes mellitus, reported 
hypertension, NYHA functional class ≥2, and baseline 
serum values of HDL and glucose. An additional multi-
variate model was constructed including lipid-lowering 
medication initiated during the BIP study or the extended 
follow-up period (total 8  years’ duration) introduced as 
a time dependent covariate. Proportionality of hazard 
assumption was verified in all models.
We further undertook interaction term analysis in 
order to explore mortality associated with fibrate vs. 
placebo treatment by TG group (below 200  mg/dL vs. 
≥200 mg/dL) with the covariates described above.
All statistical tests were two-sided, and a P value of 
less than 0.05 was considered to indicate statistical 
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significance. The P values for interaction are reported. 
Analyses were carried out with the use of SPSS software, 
version 22 (IBM Inc.) and SAS, version 9.3.
Results
The present study included patients from the original BIP 
cohort: 1548 patients allocated to the bezafibrate group 
and 1542 patients allocated to the placebo group. Clini-
cal characteristics, laboratory values, and medical ther-
apy were similar in the 2 original study treatment groups 
(Additional file  1: Table A). Nearly 80  % of the patients 
had a history of MI, and 10 % had treated diabetes mel-
litus. Beta-blockers were prescribed to nearly 40  % of 
study patients, calcium-channel blockers to 50  %, and 
angiotensin-converting enzyme inhibitors to 12 %.
Patients with triglycerides ≥200 mg/dL (n = 458) were 
equally distributed among the 2 study groups (15  % in 
both placebo and bezafibrate groups). There was no 
significant difference in characteristics of patients with 
TG ≥200 mg/dL randomized to the placebo (n = 224) vs. 
fibrate (n = 234) treatment arm (Table 1).
Compared to patients with TG <200  mg/dL patients 
with baseline TG ≥200  mg/dL presented with similar 
clinical features, with the exception of a higher BMI and 
younger age. Laboratory values differed significantly, 
including lower HDL and lower LDL and higher fasting 
glucose levels (all p < 0.001; Additional file 2: Table B).
Entire study population mortality
During the follow-up period 1869 patients died (61  %), 
952 (62  %) in the placebo group and 917 (60  %) in the 
bezafibrate group (Fig. 1). Following multivariate adjust-
ment, allocation to the bezafibrate arm was associated 
with significant 10 % mortality risk reduction (HR 0.90; 
95  % CI 0.82–0.98, p =  0.026; Table  2). Variables asso-
ciated with significantly increased mortality risk were 
Table 1 Baseline Clinical and Laboratory characteristics of patients with baseline TG ≥200 mg/dl by original study alloca-
tion
Values are presented as n (%) or mean ± SD
AP angina pectoris, ACE angiotensin-converting enzyme, BMI body mass index, COPD chronic obstructive pulmonary disease, DM diabetes mellitus, HDL-C high-
density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, LLD lipid-lowering drug, MI myocardial infarction, NYHA New York Heart Association
Bezafibrate group (n = 234) Placebo group (n = 224) P value
Clinical characteristics
 Age, years 58 ± 7 58 ± 7 0.62
 Male 210 (90) 199 (89) 0.75
 Hypertension 78 (33) 80 (36) 0.61
 DM 28 (12) 21 (9) 0.37
 BMI, kg/m2 28 ± 4 28 ± 3 0.81
 NYHA functional class ≥2 71 (30) 53 (25) 0.41
 AP class ≥2 72 (30) 53 (23) 0.40
 Prior MI 173 (74) 171 (76) 0.60
 COPD 4 (2) 8 (4) 0.22
Medical therapy
 Anti-platelets 157 (67) 155 (69) 0.63
 Beta-blockers 116 (49) 94 (42) 0.10
 Nitrates 114 (51) 127 (54) 0.47
 Ca2+-blockers 107 (46) 116 (52) 0.11
 ACE inhibitors 30 (13) 27 (12) 0.80
 Diuretics 27 (11) 36 (16) 0.16
 Non-study LLD 136 (58) 122 (54) 0.40
Laboratory values
 Glucose 104 ± 18 103 ± 19 0.76
 Total cholesterol 215 ± 18 216 ± 18 0.46
 HDL-C 31 ± 5 32 ± 5 0.14
 LDL-C 138 ± 17 140 ± 17 0.74
 Triglycerides 235 ± 25 235 ± 29 0.94
 Fibrinogen 361 ± 74 355 ± 75 0.37
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history of a past MI (HR 1.45; CI 0.92–0.98), NYHA 
class >1 (HR 1.13; CI 1.04–1.22), diabetes (HR 1.34; CI 
1.14–1.58), older age, higher BMI and glucose levels (all 
p < 0.01; Table 2).
Mortality in TG sub‑groups
Next, we divided our cohort according to their baseline 
triglyceride levels by original study allocation. Patients 
with baseline triglycerides ≥200 mg/dL allocated to pla-
cebo (n  =  224) and bezafibrate groups (n  =  234) were 
compared. Patients that were treated with bezafibrate 
had a non-significant unadjusted survival benefit (57 vs. 
62 %; Log rank p value = 0.14).
Multivariate analysis demonstrated a 25  % adjusted 
all-cause mortality risk reduction in patients with hyper-
triglyceridemia treated by bezafibrate (HR 0.75; CI 95 % 
0.60–0.94; p  =  0.012; Fig.  2). Variables associated with 
significantly increased mortality risk in this subgroup 
were: age, past MI, use of non-study lipid lowering medi-
cation, and diabetes mellitus (Table 3).
Interaction term analysis demonstrated that the 
adjusted risk reduction associated with fibrate treatment 
compared to placebo is associated with a 21 % risk reduc-
tion (HR 0.79; CI 0.63–0.98; p =  0.03) in subjects with 
elevated TG whereas this effect was not significant in the 
group with lower TG values (p for interaction  =  0.11; 
Fig. 3).
Discussion
There are two main findings in this long-term study 
which based on the intention-to-treat principle with 
more than 52,000 person-years of follow-up. First, 
patients treated during original BIP trial period by bezafi-
brate experienced a modest but significant 10  % reduc-
tion in the adjusted risk of mortality compared with 
patients allocated to the original placebo group. Second, 
the long-term benefit of bezafibrate was more prominent 
Fig. 1 Long-term survival estimates by study drug allocation for the 
entire study population
Table 2 Independent predictors of  all-cause mortality 
at 20 years of the entire study cohort
Model further adjusted for hypertension, gender, baseline HDL and use of non-
study lipid lowering medication as a time dependent covariate
HR 95 % CI P value
Lower Upper
Fibrate treatment 0.90 0.82 0.98 0.026
Past MI 1.45 1.30 1.64 <0.001
Glucose (per 1 mg/dl) 1.01 1.005 1.01 <0.001
Age (per year increment) 1.09 1.08 1.10 <0.001
BMI (per unit) 1.03 1.01 1.04 <0.001
NYHA functional class ≥ II 1.13 1.04 1.22 0.005
TG ≥200 mg/dl 1.04 0.92 1.18 0.52
Diabetes mellitus 1.34 1.14 1.58 <0.001
Fig. 2 Adjusted survival probability by original study allocation 
of bezafibrate vs. placebo in patients with TG ≥200 mg/dL&. & Cox 
proportional hazard regression model adjusted for age, gender, 
hypertension, past MI, baseline glucose, BMI, NYHA ≥ II, HDL-C and 
diabetes status
Table 3 Independent predictors of  all-cause mortality 
at 20 years in the sub group with baseline TG ≥200 mg/dL
Model further adjusted for hypertension, gender and non-study lipid lowering 
medication as a time dependent covariate (all p > 0.05)
HR 95 % CI P value
Lower Upper
Fibrate treatment 0.75 0.60 0.94 0.012
Past MI 1.53 1.15 2.00 0.004
Glucose 1.00 0.99 1.01 0.12
Age (per year increment) 1.08 1.07 1.11 <0.001
BMI (per unit) 1.01 0.98 1.05 0.39
NYHA functional class ≥ II 1.09 0.89 1.33 0.41
HDL-C (per 1 mg/dl) 1.00 0.97 1.02 0.76
Diabetes mellitus 1.88 1.36 2.61 <0.001
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among patients with hypertriglyceridemia (25 % mortal-
ity adjusted risk reduction).
Fibrates are used in clinical practice for the past half 
century mainly due to their ability to decrease TG. All 
fibrates are peroxisome proliferators-activated receptors 
α agonists with ability to enhance the oxidation of fatty 
acids in liver and muscle and reduce the rate of hepatic 
lipogenesis, thereby reducing secretion of very-low-den-
sity lipoprotein TG. Other important effects of fibrates 
include an increase of HDL level, activity of lipoprotein 
lipase, the size of LDL particles and a decrease in the 
apolipoprotein CIII concentration [14, 15].
The beneficial effects of all major fibrates (gemfibrozil, 
fenofibrate, bezafibrate) on cardiovascular events could 
be clearly demonstrated only in patients with dyslipi-
demia (mainly hypertriglyceridemia) or metabolic syn-
drome. Metabolic syndrome is an important prognostic 
sign [16]. In patients without these metabolic abnor-
malities these effects were absent [9, 17–21]. In a meta-
analysis of dyslipidemic subgroups from 5 randomized 
control trials (RCT) with fibrates totaling 4726 patients, a 
35 % relative risk reduction in cardiovascular events was 
observed compared with a non-significant 6 % reduction 
in patients without dyslipidemia [22]. Meta-analysis per-
formed in a general population [23] reflecting a blend of 
effects in patients with and without dyslipidemia (45,058 
participants) effect of fibrate therapy was reduced, pro-
ducing only a modest but still significant 10 % RR reduc-
tion for major cardiovascular events and a 13  % RR 
reduction for coronary events. In these circumstances, 
the main determinant of the overall results of the fibrate’s 
trial is mainly dependent of the number of the included 
appropriate patients with dyslipidemia and/or metabolic 
syndrome.
From the modern point of view, patients who fulfilled 
inclusion criteria of the BIP trial should been treated pri-
mary by statins and not by fibrates. In fact, about 50 % of 
the patients in the BIP trial were presented with high LDL-C 
and low TG and probably did not need fibrates at all. In 
1994 the Scandinavian Simvastatin Survival Study (4S) 
conclusions became available [24] and statins were admin-
istered to an increasing number of patients participat-
ing in the BIP trial in direct discordance with its protocol. 
Because of worse lipids profile of placebo-allocated patients 
they received statins in significantly greater proportion dur-
ing the late period of the trial. Consequently, the wide use 
of non-study statins led to attenuation of the bezafibrate’s 
effect. After the cessation of the BIP trial the rate of use of 
statins increased substantially in entire study population 
and eventually was similar in both treatment groups [25].
After publication of the results from the extended 
phase of the UKPDS trial [26] the concept of “glycemic 
legacy” was widely discussed. In the 10-year post-trial 
follow-up, patients with type 2 diabetes originally allo-
cated to intensive hypoglycemic treatment had a sig-
nificant reduction in the risk of all-cause mortality after 
the cessation of randomized interventions. These results 
were obtained although there were no longer differences 
in HbA1c values between patients originally assigned to 
conventional or intensive-treatment groups.
To the best of our knowledge, our study is the first 
which demonstrated in patients with CAD and particu-
larly in patients with hypertriglyceridemia the presence 
of long term “metabolic memory” for lipids-modified 
effects of bezafibrate. Our data together with the results 
from the extended phase of the UKPDS and STENO 2 
trials [26–28] provide evidence that the beneficial results 
of the effective management of cardio-metabolic risk fac-
tors could be seen over many years even after the cessa-
tion of treatment. Pooled together, these findings support 
the possible positive role of a “metabolic legacy” for 
patients with high cardiovascular risk, rather than only a 
“glycemic legacy” for diabetic patients.
Currently statins are the cornerstone of the treat-
ment and prevention of cardiovascular diseases related 
to atherosclerosis including CAD [29–32]. Nonetheless, 
despite the almost universal use of statins in the setting 
of secondary prevention of CAD, significant residual car-
diovascular risk is still present, especially in patients with 
hypertriglyceridemia and metabolic syndrome [1, 33]. 
The current guidelines recommend considering com-
bination fibrate-statin therapy for patients when statin 
therapy alone is not adequate to achieve lipid goals [29, 
32, 34]. Despite the strong theoretical background, there 
are only few hard outcomes data regarding combined 
Fig. 3 Independent effect of the adjusted risk reduction associated 
with bezafibrate vs. placebo treatment by pre-specified triglyceride 
group interaction*. P value for interaction of TG group by treatment 
allocation = 0.11. *Model further adjusted for age, gender, HDL-C, 
diabetes, past MI, BMI and glucose levels
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bezafibrate and statin treatment: one small randomized 
study [35] and number of observational studies [36–38]. 
In these observations bezafibrate/statin treatment was a 
safe and was associated with a lower incidence of major 
cardiovascular events compared with statins alone. Ben-
eficial effects of long-term combination therapy with 
bezafibrate and ezetimibe in patients with dyslipidemia 
were also reported [39]. Probably, combined bezafibrate/
statin or bezafibrate/ezetimibe therapy will be more 
effective in achieving a comprehensive lipid control and 
residual cardiovascular risk reduction and theoretically 
might prevent statin-associated new-onset diabetes [40].
Study limitations
The present study is limited by the post hoc nature of the 
analysis of the BIP study. It should also be noted that the 
significant long-term effects of bezafibrate therapy could 
be observed only after adjustment for important estab-
lished prognostic predictors including initiation of statins 
during the double-blind phase of the BIP trial. We do not 
have information regarding medications or events after 
the cessation of the BIP trial beyond all-cause mortality 
nor can we account for changes in medical practice and 
management guidelines over the long follow-up period. 
Therefore, further studies are needed to determine the 
possible long-term mortality benefit of bezafibrate in the 
current era of universal statin-based secondary preven-
tion in CAD patients.
Conclusions
Patients treated during the original BIP trial period 
by bezafibrate experienced a modest but significant 
10  % reduction in the adjusted risk of mortality dur-
ing extended follow-up of 20 years. The long-term ben-
efit of bezafibrate was more prominent among patients 
with baseline hypertriglyceridemia (25  % mortality risk 
reduction). The present findings suggest that bezafibrate 
in patients with CAD and hypertriglyceridemia could be 
associated with a significant long-term mortality reduc-
tion that extends far beyond the period of active treat-
ment with the drug.
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